A multicenter retrospective study assessing ipilimumab or the combination of ipilimumab plus nivolumab after anti-PD-1 treatment failure, in advanced melanoma patients

Trial Profile

A multicenter retrospective study assessing ipilimumab or the combination of ipilimumab plus nivolumab after anti-PD-1 treatment failure, in advanced melanoma patients

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2017 New trial record
    • 16 Feb 2017 Results published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top